To determine whether cyclosporine (0.05%) can safely and effectively accelerate corneal nerve regeneration after LASIK, thereby
facilitating faster recovery of corneal sensitivity.
This prospective, randomized, single-center clinical study comprised 44 eyes of 22 patients scheduled to undergo bilateral
LASIK. One eye was randomly assigned to receive cyclosporine drops twice daily for 3 months in addition to standard postoperative LASIK
medication. Corneal sensitivity was measured using the Cochet-Bonnet esthesiometer in four areas outside and five areas inside the LASIK
flap preoperatively and at 1 day, 1 week, 1 month, and 3 months postoperatively. Safety parameters of best spectacle-corrected visual
acuity and the incidence of adverse events were also collected.
For all four points outside the LASIK flap, normal corneal sensitivity was maintained throughout the study. In addition, no
significant difference was found between the cyclosporine-treated eyes and the control eyes at these points. All points within the LASIK
flap except the point closest to the hinge demonstrated profound corneal hypoesthesia at 1 day, 1 week, and 1 month postoperatively with
no differences noted between the control and cyclosporine-treated eyes. These same points had statistically significantly greater
corneal sensitivity in the cyclosporine group relative to the control group (P<.011) at 3 months postoperatively.
Cyclosporine was shown to significantly improve corneal sensitivity at 3 months after LASIK, which suggests that topical
cyclosporine promotes enhanced corneal nerve regeneration. [J Refract Surg. 2008;24:337-343.]
ABOUT THE AUTHORS
From the Department of Ophthalmology, University of Arizona, and Arizona State University, Manicopa Hospital and Associated Retinal
Consultants, Phoenix, Ariz (Peyman); University of Illinois Eye and Ear Infirmary, Chicago, Ill (Sanders); and Centro Láser, Santo
Domingo, Dominican Republic (Batlle, Féliz, Cabrera).
Dr Peyman has a patent pending neuronal regeneration. The remaining authors have no financial or proprietary interest in the materials
Correspondence: Donald R. Sanders, MD, PhD, Center for Clinical Research, 242 N York Rd/Ste 102, Elmhurst, IL 60126. Tel: 630.530.9700
ext 12; Fax: 630.530.1636; E-mail: email@example.com
Received: July 5, 2007
Accepted: January 18, 2008